Epidarex Capital funds the commercialization of ground-breaking research and new technologies to address large and unmet needs in today’s healthcare market.
Submission of New Drug Application (NDA) planned for second half of 2020 following successful pre-NDA meeting with FDA WALTHAM, Mass., May 21, 2020 – Apellis Pharmaceuticals, Inc. (Nasdaq:... No cases of inflammation observed after 12 months with Phase 3 formulation of pegcetacoplan in patients with advanced geographic atrophy (GA) Decrease in mean lesion growth in nine patients with bilat...
Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Apellis Reports Analysis from Phase 1b Geographic Atrophy Study